Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

JAZZ, CHFC, RGN, MSLP, CRWE - Stock News From DrStockPick.com!

drstock-2-3

signup3m

Crown Equity Holdings Inc. (OTCBB:CRWE) is pleased to report its financial results for the nine month period ending September 30, 2010. Revenue for the nine months totaled $1,073,383 compared to $418,959 during 2009. The Company incurred an operating loss of $54,527 for the nine months ending September 30, 2010 compared to an operating loss of $36,923 during the same period in 2009. Net loss of $343,049 for the nine months ending September 30, 2010 compared to a net loss of $29,379 for the same period in 2009. The net loss in 2010 was attributed mostly to an unrealized loss of $307,544 on securities held by the Company.

Crown Equity Holdings Inc. is extending its internet footprint internationally to include the following countries; Argentina, Brazil, Canada, China, France, Germany, Hong Kong, India, Indonesia, Italy, Japan, Korea, Malaysia, Mexico, New Zealand, Pakistan, Russia, Singapore, Spain, South Africa, Taiwan, United Arab Emirates and United Kingdom.

Crown Equity Holdings Inc. is a consulting organization which provides and assists small business owners with the knowledge required in taking their company public, and has re-focused its primary vision with its aligned group of independent website divisions to providing media advertising services, as a worldwide online media advertising publisher, dedicated to the distribution of quality branding information, as well as search engine optimization for its clients. The company announced in June of this year its 1- 10 forward stock split.

************************************

MusclePharm Corporation (OTCBB:MSLP) one of the fastest growing nutritional supplement companies in the United States, announced former UFC light heavyweight champion, Lyoto Machida, will be wearing MusclePharm apparel at the main fight which takes place on Saturday, November 20, 2010 in Auburn Hills, Michigan.

UFC newcomer Maiquel Jose Falcao Goncalves will also sport MusclePharm's apparel on the UFC 123 Fight Card that includes his fight shorts, t-shirt, hat, and a banner with the MSLP Ticker Symbol. UFC 123 Event will draw an estimated 850,000 pay per view buys and is watched by an estimated 10 million viewers.

"We are very excited to have one of our UFC athletes compete in the main event fight. UFC continues to be a tremendous partner for MusclePharm as we increase our consumer demographic exposure during Saturday night's fight," commented Cory Gregory, MusclePharm's President. "We will continue to focus on opportunities with UFC to further increase MusclePharm's brand awareness and expand MusclePharm's supplement and apparel market penetration."

MusclePharm is a rapidly expanding healthy life-style company that develops and manufacturers a full line of NSF and scientifically approved, nutritional supplements that are 100% free of any banned substances. Based on years of research, MusclePharm products are created through an advanced six-stage research protocol involving the expertise of top nutritional scientists and field tested by more than 100 elite professional athletes from various sports including the NFL, MMA, and MLB. The Company's propriety and award winning products address all categories of an active lifestyle including muscle building, weight loss, and maintaining general fitness through a daily nutritional supplement regimen. MusclePharm is sold in over 120 countries and available in over 5,000 US retail outlets that include GNC, and Vitamin Shoppe, as well as over 100 online stores, including bodybuilding.com, Amazon and Vitacost.com.

************************************

RegeneRx Biopharmaceuticals, Inc. (AMEX:RGN) announced recently that the Company received a patent in Australia using thymosin beta 4 for the treatment of a broad array of gastrointestinal infections and disorders. The patent expires in 2023. RegeneRx has patents pending for this use in a number of countries, including the U.S.

RegeneRx is focused on the development of a novel therapeutic peptide, Thymosin beta 4, or T?4, for tissue and organ protection, repair and regeneration. RegeneRx currently has three products in clinical development.

************************************

Chemical Financial Corporation (NASDAQ:CHFC) recently announced 2010 third quarter net income of $8.9 million, or $0.32 per diluted share, compared to net income of $4.4 million, or $0.17 per diluted share, in the second quarter of 2010 and $2.5 million, or $0.10 per diluted share, in the third quarter of 2009.

Chemical Financial Corporation operates as the holding company for Chemical Bank that offers commercial banking services in Michigan.

************************************

Jazz Pharmaceuticals, Inc. (NASDAQ:JAZZ) recently announced financial results for the third quarter ended September 30, 2010, and updated financial guidance for 2010. The company’s updated 2010 financial guidance reflects higher expected sales of XYREM oral solution and lower expected expenses. Total revenues for the quarter ended September 30, 2010 were $44.8 million, up 45 percent compared to $30.8 million for the quarter ended September 30, 2009.

Jazz Pharmaceuticals is a specialty pharmaceutical company focused on identifying, developing and commercializing innovative products to meet unmet medical needs in neurology and psychiatry.

***************************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

drstbc

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (OTCPK:CRWE) has received five thousand dollars and anticipates receiving another forty five thousand dollars in cash from a third party for 30 (thirty) days of advertising for MusclePharm Corporation (OTCQB:MSLP)